Trigoderm Gel 0.5 % w/w Fusidic acid, 0.1 % w/w Betamethasone

Land: Irland

Sprache: Englisch

Quelle: HPRA (Health Products Regulatory Authority)

Wirkstoff:

Fusidic acid; Betamethasone valerate

Verfügbar ab:

Dechra Veterinary Products A/S

ATC-Code:

QD07CC01

INN (Internationale Bezeichnung):

Fusidic acid; Betamethasone valerate

Dosierung:

0.5, 0.1 percent weight/weight

Darreichungsform:

Gel

Verschreibungstyp:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapiegruppe:

Dogs

Therapiebereich:

betamethasone and antibiotics

Anwendungsgebiete:

Antibacterial

Berechtigungsstatus:

Authorised

Berechtigungsdatum:

2004-03-19

Fachinformation

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Trigoderm Gel 0.5 % w/w Fusidic acid, 0.1 % w/w Betamethasone
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
White gel
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dog.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the topical treatment of surface pyoderma in the dog such as acute
moist dermatitis ('hot spots') and intertrigo (skin
fold dermatitis).
4.3 CONTRAINDICATIONS
Do not use in animals with hypersensitivity to any of the components.
Discontinue use if hypersensitivity develops to
the product.
Do not use for the treatment of deep pyoderma as glucocorticoids are
contra-indicated in this condition.
Do not use where fungal infection is present.
Do not apply to the eye.
ACTIVE SUBSTANCES:
Fusidic acid
0.5
% w/w
Betamethasone (as the valerate ester)
0.1
% w/w
PRESERVATIVES:
Methylparahydroxybenzoate (E218)
0.27 % w/w
Propylparahydroxybenzoate (E216)
0.03 % w/w
For a full list of excipients see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_9_
_/_
_0_
_1_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_9_
_6_
_3_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The dog should be prevented from licking treated lesions and so
ingesting the product.
Where there is a risk of trauma,
preventative measures such as the use of an Elizabethan collar should
be considered.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL P